Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × Introns × Clear all
NCT02615574 2017-09-26

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

University of Pittsburgh

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡